Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351335 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC8NPC1RAB9A | |
| SCHEMBL124591 | 0.84 | HDAC6 (0.71) | HDAC6SMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL2571205 | 0.83 | HDAC6 (0.71) | HDAC6HDAC1HDAC8NPC1RAB9A | |
| SCHEMBL2943788 | 0.82 | HDAC6 (0.69) | HDAC6HDAC1HDAC8NPC1SMN1; SMN2 | |
| SCHEMBL1040774 | 0.81 | HDAC6 (0.68) | HDAC6RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29353516 | 0.81 | HDAC6 (0.68) | HDAC6RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7403954 | 0.80 | HDAC6 (0.67) | HDAC6HDAC1KMT2AMEN1SIGMAR1 | |
| SCHEMBL7137884 | 0.79 | HDAC6 (0.65) | HDAC6SMN1; SMN2TDP1CYP3A4 | |
| SCHEMBL2566149 | 0.78 | HDAC6 (0.64) | HDAC6HDAC1HDAC8NPC1RAB9A | |
| SCHEMBL5806008 | 0.78 | HDAC6 (0.63) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| CN-119055776-A | Application of ACSL1 in relieving and treating neurodegenerative diseases | 北京市神经外科研究所 | 2024-12-03 | — | — | CN | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230126987-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | GENEROS BIOPHARMA LTD. (KY) | 2023-04-27 | — | — | US | disclosed |
| CN-114957396-B | Anti-inflammatory active peptide and application thereof | 江南大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-4125894-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | Generos Biopharma Ltd. (KY) | 2023-02-08 | — | — | EP | disclosed |
| CN-115484953-A | Methods of treating cytokine storm syndrome and related diseases | 健艾仕生物医药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-2363122-A1 | Clonidine to treat pain locally | Medtronic, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2296632-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | Otonomy, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2010008995-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090177228-A1 | Coated suture thread and production thereof | OPTOVENT AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-2043625-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | Medtronic, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1888133-A1 | COATED SUTURE THREAD AND PRODUCTION THEREOF | Optovent AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008014066-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2006126926-A1 | COATED SUTURE THREAD AND PRODUCTION THEREOF | OPTOVENT AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | HDAC6 1729/4885HDAC1 2109/4885HDAC8 1949/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | HDAC6 2551/4885HDAC1 3527/4885HDAC8 3264/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | HDAC6 4351/4885HDAC1 4825/4885HDAC8 4598/4885 |
| US-20230126987-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | IL6, IL2, IL15 | HDAC6 1143/4885HDAC1 2991/4885HDAC8 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.